ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013

New NIH Grant Program or Young Investigators

October 8, 2010

Capitol Hill: Trial Results Represent Culmination of Research, Klausner Tells House

March 19, 1999

Conversation with The Cancer Letter: Daniel Hayes Leads Tour of Caris Website

August 8, 2014

NCI Cooperative Group Clinical Trials Approved

July 31, 2009

BSA Approves Six Concepts

July 19, 2013